Trial Profile
A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2021
Price :
$35
*
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- Sponsors Valneva
- 05 Jul 2021 According to an Valneva media release, Prof. Thomas Jelinek, will present the data from this trial at a virtual symposium titled, Developing new vaccines to protect against infectious diseases at home and abroad on July 9, 2021 at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- 08 Sep 2020 According to a Valneva media release, this study served as a basis for the companys End of Phase 2 meeting with the U.S. FDA and supported the direct progression into Phase 3.
- 02 Jun 2020 According to a Valneva media release, full data from this trial were published in the peer-reviewed medical journal The Lancet Infectious Diseases.